Moreover, another phase I trial explored the feasibility and safety of off-the-shelf allogeneic IL-13Rα2-targeted CAR-T cells that were genetically engineered to resist treatment with glucocorticoids, which are commonly prescribed to control cerebral edema and inflammation in GBM, in six patients with unresectable recurrent GBM [62]. The gene discussed is IL13RA2; the disease is glioblastoma.